CSIMarket
 
Aileron Therapeutics Inc   (ALRN)
Other Ticker:  
 
 
Price: $5.5800 $0.05 0.904%
Day's High: $5.675 Week Perf: 0.54 %
Day's Low: $ 5.50 30 Day Perf: 19.23 %
Volume (M): 15 52 Wk High: $ 6.12
Volume (M$): $ 84 52 Wk Avg: $2.31
Open: $5.50 52 Wk Low: $1.01



 Market Capitalization (Millions $) 25
 Shares Outstanding (Millions) 5
 Employees 62
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -13
 Cash Flow (TTM) (Millions $) 7
 Capital Exp. (TTM) (Millions $) 0

Aileron Therapeutics Inc
Aileron Therapeutics Inc. is a clinical-stage biopharmaceutical company in the United States of America, founded in 200 The company is focused on the discovery, development, and commercialization of novel RNA-targeted therapeutics for cancer and other diseases. Aileron's proprietary platform technology, called Stapled Peptide Technology, enables the development of drug candidates that can selectively target intracellular and extracellular proteins.

Aileron's lead product candidate, ALRN-6924, is a first-in-class, dual MDM2/MDMX inhibitor for the treatment of solid tumors and hematologic malignancies. The drug works by restoring the function of tumor suppression proteins, p53 and p73, that are typically inactivated in cancer. ALRN-6924 is currently being evaluated in multiple phase 1 and 2 clinical trials for various types of cancer, including acute myeloid leukemia (AML), small cell lung cancer (SCLC), and tumors with p53-mutant alterations.

In addition to ALRN-6924, Aileron has a pipeline of drug candidates based on its Stapled Peptide Technology platform that are in various stages of preclinical development. These candidates target key intracellular and extracellular proteins involved in cancer, immunology, and other conditions.

Aileron has partnerships and collaborations with several leading pharmaceutical companies, including Roche, Lilly, and Celgene. These partnerships provide Aileron with access to resources and expertise to further advance its drug candidates and platform technology.

Aileron has a highly experienced management team and board of directors, with over 100 years of combined experience in drug development and commercialization. The company is headquartered in Boston, Massachusetts, and has a research and development facility in Cambridge, Massachusetts.

Overall, Aileron Therapeutics Inc. is a promising biopharmaceutical company dedicated to advancing novel RNA-targeted therapeutics for the treatment of cancer and other diseases. With a strong pipeline of drug candidates and partnerships with leading pharmaceutical companies, the company is well-positioned to make significant contributions to the field of oncology and beyond.


   Company Address: 738 Main Street Waltham 2451 MA
   Company Phone Number: 995-0900   Stock Exchange / Ticker: NASDAQ ALRN
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Aileron Therapeutics Inc

Aileron Therapeutics Inc Suffers Significant Operating Shortfall of $-1.983 Million in Q3 2023, Raising Concerns about Future Stability

Aileron Therapeutics Inc, a small player in the Major Pharmaceutical Preparations sector, recently reported its earnings for the third quarter of 2023. Despite the company still operating at a shortfall of $-1.983 million, it is worth noting that Aileron Therapeutics Inc has shown significant improvement compared to the same period last year, where the operating shortfall stood at $-6.482 million.
While there is still a deficit, it is encouraging to see that the company has managed to reduce it from the previous year. Aileron Therapeutics Inc's financial results for the third quarter of 2023 show a shortfall of $-1.827 million, compared to $-6.368 million in the same period in 2022. This improvement in the company's bottom line is a significant take away from this financial interval.

Aileron Therapeutics Inc

Aileron Therapeutics Inc Emerges as a Strong Contender in Pharmaceutical Preparations Sector with Promising Financials\Aileron Therapeutics Inc Delivers Impressive Results, Outshining Competitors in Pharmaceutical Preparations Sector\Aileron Therapeutics Inc Reports Significant Improvement in Financial Performance, Solidifying its Position in the Industry\Innovative Approach Fuels Aileron Therapeutics Inc's Financial Success in Pharmaceutical Preparations Sector\Aileron Therapeutics Inc's Financials Surge Ahead, Demonstrating Potential for Growth in the Healthcare Industry

Aileron Therapeutics Inc Shows Promise with Improved Financials
Leading pharmaceutical preparations companies in the industry may have to keep a watchful eye as smaller businesses are making their presence known. Aileron Therapeutics Inc recently announced its financial results for the second quarter of 2023, revealing an operating loss of $-1.992 million. While this may seem concerning at first glance, it should be viewed as a positive development considering the significant improvement from the same period last year when the operating loss was $-8.041 million.
The notable reduction in operating losses is reassuring for market participants, serving as an affirmation of Aileron Therapeutics Inc's potential in the industry. Furthermore, the company's losses have receded to $-1.787 million from $-7.992 million in the second quarter of 2022, indicating a positive trend that will undoubtedly support its aspirations to become a leading player in the healthcare sector.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com